Acer Therapeutics

Cambridge, United States Founded: 1991 • Age: 35 yrs Listed Acquired By Zevra
Treatments for ultra-rare diseases like vEDS and MSUD are developed.

About Acer Therapeutics

Acer Therapeutics is a Healthcare company based in Cambridge (United States) founded in 1991 by Chris Schelling, and was acquired by Zevra in November 2023. Treatments for ultra-rare diseases like vEDS and MSUD are developed. The company has 37 employees. Acer Therapeutics has completed 1 acquisition, including Opexa Therapeutics. Its chief executive, as recorded, is Chris Schelling. Acer Therapeutics offers products and services including OLPRUVA, EDSIVO, and Investigational Lifecycle Opportunities. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its competitors include Alnylam, Ultragenyx and Gemini Therapeutics; 3 of its 3 listed competitors have raised funding.

Company details

Acer Therapeutics is developing treatments for ultra-orphan diseases. Its drug portfolio includes ACER-002 for Vascular Ehlers-Danlos Syndrome (vEDS) for which Acer was awarded orphan drug designation by the FDA in January 2015and ACER-001 (orphan drug designation by the FDA in August 2014) for Maple Syrup Urine Disease (MSUD), EDS is a group of hereditary disorders of connective tissue and MSUD is a devastating genetic disease an inborn error of amino acid metabolism. ACER-001 is a reformulation of sodium phenylbutyrate (NaPBA) while Acer is repurposing celiprolol, a unique beta-blocker for the treatment of vEDS.

  • Headquarters Cambridge, United States
  • Employees 37
  • Founders Chris Schelling
  • Stage Acquired
  • Sectors
    Healthcare
  • Website acertx.com
  • Social LinkedIn X Facebook
  • Acquired by Zevra (Nov 2023)
Operational Areas
Key Metrics
  • Annual Revenue
    $1.26 M (USD)
    as on Dec 31, 2021
  • Latest Funding Round
    $1.5M (USD), Post-IPO

    Dec 2022

  • Investors
    Zevra

    & 1 more

  • Employee Count
    37
  • Investments & Acquisitions
  • Acquired by
    Zevra

    (Nov 2023)

Products & Services of Acer Therapeutics

Acer Therapeutics offers a comprehensive portfolio of products and services, including OLPRUVA, EDSIVO, and Investigational Lifecycle Opportunities.

OLPRUVA
Therapy

Treatment for Maple Syrup Urine Disease conditions

EDSIVO
Therapy

Investigational treatment for Vascular Ehlers-Danlos Syndrome

Investigational Lifecycle Opportunities
Research Pipeline

Explores new therapies for ultra-rare diseases

Funding Insights of Acer Therapeutics

  • Total Rounds 7
  • Last Round Post-IPO β€” $1.5M
  • First Round $2.1M

    (Apr 2015)

  • Investors Count 1

All 7 funding rounds of Acer Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2022$1.5MPost-IPO––
–
Jul 2020$857,493Post-IPO––
–
Dec 2017$1.26MPost-IPO––
–
Oct 2017$15.67MPost-IPO––
–
Apr 2017$3.13MPost-IPO––
–
May 2016$8.15MPost-IPO––
Apr 2015$2.1MPost-IPO––
–
Valuation history

2 investors in total: 2 institutional.

Investors in Acer Therapeutics

Acer Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Zevra and TVM Capital Life Science.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Capital is invested in life science innovations for healthcare transformation.
tvm-capital.comMunich, Germany
Marketing services are provided to biopharma companies.
2006zevra.comCelebration, United States
Premium access

Investor details for Acer Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Acer Therapeutics

29 people are tracked at Acer Therapeutics (24 in leadership, 5 in team); the tracked headcount is 37.

NameRoleGroup
Chris Schelling
Founder & CEOLeadership
Lauren Hitchins
Director, Strategic Operations And Medical ExcellenceLeadership
David Rowe Wood
Head Of Field Medical AffairsLeadership
Adrian Quartel
Chief Medical OfficerLeadership
Timothy Sangiovanni
Senior Vice President, Corporate ControllerLeadership
Neil F. McFarlane
President and Chief Executive OfficerLeadership
Rene A. Braeckman
Senior Vice President, Clinical DevelopmentLeadership
Laduane Clifton
Chief Financial Officer, Secretary And TreasurerLeadership
R. Laduane Clifton
Chief Financial Officer, Secretary, & TreasurerLeadership
Christopher M. Lauderback
Senior Vice President, ManufacturingLeadership
Adam Smith
Vice President, Business Development And Commercial OperationsLeadership
Louise Himmelstrup
Vice President EU Regulatory AffairsLeadership
Sven Guenther
Chief Scientific OfficerLeadership
Sanjib Bera
VP Drug DiscoveryLeadership
Abbi M.
Vp, Legal AffairsLeadership
Douglas Commerce
Sr. Director, CMC Quality AssuranceLeadership
Tanya Hayden
Senior Vice President, Chief Of StaffLeadership
Mark Meier
Sr. Director, MarketingLeadership
Nichol Ochsner
Vice President, Investor Relations And Corporate CommunicationsLeadership
Corinna Wetzel
Senior Director Product DevelopmentLeadership

9 more people are available in the full profile.

Premium access

Complete people profiles for Acer Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Acer Therapeutics

Acer Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Opexa Therapeutics.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Developing personalized T-cell therapies to treat autoimmune diseases, including multiple sclerosis.
opexatherapeutics.comThe Woodlands, United States2004Jul 2017β€’β€’β€’β€’
Premium access

Complete acquisition details for Acer Therapeutics

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Acer Therapeutics

6 dated milestones of Acer Therapeutics across 32 years, from founding to its latest funding, stage changes and deals.

  1. Founded Acer Therapeutics is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $2.1M.
  4. Acquisition Acquires Opexa Therapeutics.
  5. Funding Latest funding round, Post-IPO, of $1.5M.
  6. Exit Acquired by Zevra.

Competitors of Acer Therapeutics

Acer Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Alnylam, Ultragenyx and Gemini Therapeutics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
alnylam.com2002Cambridge, United States$17M2,100
RNA interference-based therapeutics are developed for multiple disorders.
ultragenyx.com2010Novato, United States$135.1M837
Therapeutics for rare and ultra-rare metabolic diseases are developed.
geminitherapeutics.com2015Cambridge, United States$44.5M45
Developer of precision therapeutics for dry AMD and rare genetic diseases
Premium access

Detailed competitors of Acer Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Rare Diseases

3 companies that operate in the same segment as Acer Therapeutics (Rare Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Gene therapies for rare diseases including retinal dystrophies are developed.
2013Philadelphia, Pennsylvania, United StatesUSD 82.8 MUSD 64.73 M822
Therapeutics for genetic diseases are developed through targeted interventions.
2015Palo Alto, California, United StatesUSD 434.2 MUSD 502.08 M730
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Acer Therapeutics

Premium access

Complete news archive for Acer Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Acer Therapeutics

Acer Therapeutics was founded in 1991 and raised its 1st funding round 24 years after it was founded.

Acer Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Chris Schelling is the CEO of Acer Therapeutics, as recorded in our data. They have also founded this company.

Acer Therapeutics has 37 employees.

Annual revenue of Acer Therapeutics is $1.26M as on Dec 31, 2021.

Acer Therapeutics is developing treatments for ultra-orphan diseases. Its drug portfolio includes ACER-002 for Vascular Ehlers-Danlos Syndrome (vEDS) for which Acer was awarded orphan drug designation by the FDA in January 2015and ACER-001 (orphan drug designation by the FDA in August 2014) for Maple Syrup Urine Disease (MSUD), EDS is a group of hereditary disorders of connective tissue and MSUD is a devastating genetic disease an inborn error of amino acid metabolism. ACER-001 is a reformulation of sodium phenylbutyrate (NaPBA) while Acer is repurposing celiprolol, a unique beta-blocker for the treatment of vEDS.

Acer Therapeutics's top competitors include Alnylam, Ultragenyx and Gemini Therapeutics.

Acer Therapeutics offers OLPRUVA, EDSIVO, and Investigational Lifecycle Opportunities.

Acer Therapeutics has made 1 acquisition, including Opexa Therapeutics.

Acer Therapeutics has 2 investors. Key investors include Zevra, and TVM Capital Life Science.

Yes. Acer Therapeutics was acquired by Zevra in November 2023.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available